Sustainable Innovation
Expanding our portfolio without losing sight of the resources it takes.
A research pipeline built for the long run
Zynsera brings a track record of making generics affordable and accessible, backed by a robust R&D pipeline. We continually expand our portfolio and focus on unmet needs, redefining what's possible for better health outcomes — without losing sight of the resources it takes to get there.
Pipeline Discipline
New formulations are prioritised against real, documented gaps in therapeutic access.
Resource-Aware Manufacturing
Production processes designed to reduce waste, water and energy intensity over time.
Access-First R&D
Innovation measured by how many more patients can afford treatment, not novelty alone.
Innovative & specialty medicines
We are continually building our specialty and innovative branded pharmaceutical portfolio, with a catalogue of branded products across a variety of therapeutic areas — providing breakthrough treatments where they are needed most.
Read more about how this connects to our wider environmental commitments on our Sustainability pages.